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Introduction
The diagnosis of growth hormone deficiency 
(GHD) or excess in a child or adult with impaired 
or abnormal growth cannot be made on the basis of 
auxological criteria alone, since these are common 
to a variety of growth disorders related to different 
causes. In our current understanding, any growth 
disorder that is caused either by impaired growth 
hormone (GH) secretion or by impaired peripheral 
action of GH can be classified as GHD and excess 
growth hormone secretion is labeled as gigantism in 
a child and acromegaly in an adult.
Normal GH secretion shows an episodic circadian 
pattern with wide intra- and inter-individual 
variation, for this reason random serum GH levels 
are of little value and provocative testing of GH 
is indicated for biochemical diagnosis of GH 
disorders. It can be stimulated by physiological 
or pharmacological ways. Sleep, fasting and 
exercise are the physiologic stimuli of the GH 
release. Pharmacological stimuli include L-dopa, 
clonidine, propranolol, glucagon, arginine, GH-
releasing hormone (GHRH) and insulin-induced 
hypoglycemia. In the diagnosis of GHD, these 
pharmological stimuli can be used alone or in a 
variety of combinations.
The provocative tests done in Section of Chemical 
Pathology, Department of Pathology and 
Microbiology are discussed below:
1) For GH Deficiency:
 l ‘Growth hormone stimulation test with insulin’ 
  or ‘Insulin hypoglycemia test (IHT)’ or 
      ‘Insulin tolerance test (ITT)’
 l Growth hormone stimulation with L-DOPA
2) For GH Excess:
	 l	Growth hormone suppression with glucose by  
  Oral glucose tolerance test (OGTT)
Growth Hormone Stimulation Test with Insulin
The patient comes to the laboratory by appointment 
and overnight fast for 10-14 hours is mandatory 
for the procedure. Test is started by taking consent, 
weighing and cannulating the patient for emergency 
I/V access. Required dose of insulin is calculated i.e. 
0.1 or 0.15 units/kg body weight. 10 cc syringe with 
25 per cent dextrose is kept ready. Baseline sample 
Provocative Testing for Growth Hormone 
Disorders
From the Editor’s Desk
Dr Noreen Sherazi & Dr Shabnum Khawaja
Chemical Pathology
The past few issues have been theme based where 
we have covered reams of new information and 
technologies on a focused subject. For a change, we 
have once again adapted a non-thematic approach 
in this issue since a lot of information can be 
disseminated by this methodology as well.
This issue contains variety of articles from 
Tathology, Microbiology and Radiology. 
Apart from increasing awareness on quality 
improvements, needle stick injuries, new markers 
for sepsis, collection technique for blood cultures 
and prognostic markers for acute myeloid 
leukemia to name a few, we have also shared 
information on genetic testing services offered 
for alpha thalassemia. In addition, the issue 
also includes information about various other 
new tests available in different sections of the 
department. 
It is hoped that this issue will further enhance 
the awareness and education of our physicians in 
diagnosing common and rare medical conditions.
Dr Natasha Ali
Haematologist
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of glucose and GH is taken and simultaneously 
patient’s glycemic status is checked on glucometer. 
After that multiple sampling of glucose and GH is 
done at 30,45,60,90 and 120 minutes. The test will 
be continued further only if blood glucose level 
drops below 50 mg/dl or <2.9 mmol or patient is 
symptomatic (i.e. there is shivering, irritability, 
drowsiness, fweating, confusion, fatigue, hunder, 
etc.) If blood glucose level doesn’t drop till 50 mg/
dl or no symptoms at all then test is repeated with 
higher insulin dose i.e. 0.15 units /kg taking 45 
minutes glucose level as baseline. 
Insulin induces hypoglycemia and as a result GH is 
released. After stimulation, for a normal individual 
GH should increase to a peak value of >10 ng/
ml when hypoglycemia is achieved. If there is GH 
deficiency this GH peak would not be observed.
Growth Hormone Stimulation Test with L-DOPA
It is pharmacological stimulus of GH to evaluate GH 
deficiency. No appointment is needed. Patient should 
fast overnight for the procedure. Consent should be 
taken and dose of L-dopa tablet for the patient is 
calculated according to weight i.e. 125 mg if weight 
is ≤ 15 kg, 250 mg if weight is 16-35 kg and 500 
mg if weight is >35 kg body weight. After baseline 
sampling for serum GH, the tablet of L-dopa should 
be ingested by the patient with few sips of water. 
Blood samples are collected at 30, 60, 90 and 120 
minutes. Please note that test should be abandoned 
if patient vomits out ingested tablet (blue vomitus) 
before 60 minutes sample.
After pharmacological stimulation, normally GH 
peaks in 30 -120 minutes and its concentration is 
far above 7.5ng/ml. Deficiency is suspected if levels 
remain below the desired cutoff.
Growth Hormone Suppression with OGTT
   
When there is clinical suspicion of acromegaly or 
gigantism GH secretion becomes autonomous it will 
not suppress with hyperglycemia, where as in normal 
individuals hyperglycemia causes GH inhibition. 
However, it should not be done in diabetic patients 
who have suppressed GH due to hyperglycemia. No 
prior appointment from the laboratory is required. 
Patient should fast overnight. After consent, baseline 
samples for GH and glucose is taken. Anhydrous 75g 
of glucose in 300 ml of cold water is given to the 
patient. Multiple sampling is done at 30, 60, 90 and 
120 minutes for GH and glucose.
Normally GH suppresses with hyperglycemia or 
glucose load to < 2ng/ml. In case of acromegaly 
patient will fail to show suppression and there will be 
paradoxical rise in GH concentration.
Please note we are also performing insulin growth 
factor 1 (IGF-1) levels at AKUH Clinical Laboratory 
for diagnosing various GH disorders. 
Frequently asked questions from Chemical 
Pathologists regarding GH stimulation with insulin:
Should the test be conducted if a patient comes 
with fasting in excess of 14 hours?
Test should not be done because over longer periods of 
fasting, liver will start to produced glucose endogenously 
by gluconeogenesis will affect the test results.
Should the test be continued if the fasting blood 
glucose is high?
Take proper history regarding meal intake and 
duration of fasting. Start the test if the fasting is 
below diabetic range.
What will you do if the patient’s blood glucose 
hasn’t dropped down at 30 minutes and patient is 
also not symptomatic? 
It means biochemical hypoglycemia not achieved. 
Wait till 45 minutes sample and if still high start the 
test with second bolus of insulin i.e. 0.15units/kg 
body weight. 
Should the test be continued if the patient’s blood 
glucose hasn’t dropped down at 30 minutes but 
patient is irritable or drowsy?
Criteria for proceeding the GH stimulation with 
insulin is either biochemical hypoglycemia i.e. 50 
mg/dl glucose or signs of hypoglycemia. In this case 
we will carry on with the procedure.
What will be the new blood glucose baseline while 
giving insulin again?
We will wait till 45 minutes sample, if glucose level 
is still high then restart the test with 45 minutes 
reading taken as baseline for glucose.
What will you do  if on repeating GH stimulation 
by insulin, blood glucose does not drop?
It could be due to various reasons; firstly if it is 
happening frequently over the past few weeks then 
check your insulin vial. If it is closer to expiry, discard 
and get a new one.  Secondly if this is the first case then 
we should suspect insulin resistance in such patients. 
Test should be abandoned and a note should be given 
or communicate with treating physician directly so 
that he is well aware about the failure of test. 
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Serum Procalcitonin for Early Sepsis Diagnosis
Dr Sibtain Ahmed
Chemical Pathology 
Table 1. Compares the Kinetics of C-reactive Peptide, Interleukins, Tumor Necrosis Factor-α with Serum Procalcitonin after a 
Bacterial Insult
Cytokines (interleukins, 
tumor necrosis factor-α)
1-3 hours
2 hours
Only remain elevated for few hours
8 hours
C-Reactive Protein
12-24 hours
48 hours
Can remain elevated without there 
being underlying infection
Late
Procalcitonin
2-4 hours
8 hours
Persists for as long as the inflam-
matory process 
continues
Early
Rise
Peaks
Relation to 
sepsis
Normalize
Procalcitonin, a protein that consists of 116 
amino acids is a peptide precursor of the hormone 
calcitonin. Procalcitonin is also produced by the 
neuroendocrine cells of the lung and intestine. It is 
released as an acute-phase reactant in response to 
pro-inflammatory stimuli, especially of bacterial 
origin. Increased levels of procalcitonin in response 
to viral infections and noninfectious inflammatory 
stimuli (autoimmune diseases and chronic 
inflammatory processes) are much less pronounced, 
rarely exceeding 0.5 ng/mL. Severe trauma, major 
burns, multi-organ failure, or major surgery can 
cause procalcitonin elevations in the absence of 
sepsis. The optimal cut-off ranges of procalcitonin 
are variable and are dependent on the clinical setting 
and the site and extent of the infection. Following are 
the clinical and diagnostic utilities of procalcitonin.
Procalcitonin Kinetics in Sepsis
Serum procalcitonin has been demonstrated to 
be an ideal biomarker for differentiating patients 
with sepsis from those with systemic inflammatory 
reaction not related to infectious cause.  Table 1 
shows the comparison of procalcitonin with other 
biomarkers used to assist sepsis diagnosis.
Differentiates Bacterial from Viral Infection
A commonly encountered situation in the clinical 
practice is that the signs and symptoms of bacterial 
and viral infections are widely overlapping, 
especially in respiratory tract infections. Sometimes 
the diagnostic uncertainty still remains, even after 
obtaining a complete clinical history, performing 
a physical examination and requesting various 
radiological/ laboratory investigations. It is often 
difficult to differentiate bacterial from viral causes 
of sepsis. Serum procalcitonin with more specificity 
for differentiating bacterial from viral infections 
considerably improves the differential diagnosis in 
these cases. Procalcitonin released as an acute-phase 
reactant is associated with bacterial endotoxin and 
inflammatory cytokines and it does not increase in 
viral infections.
Prognostic Marker of Sepsis
Increased levels of procalcitonin are also reported 
to be associated with higher SOFA (Sequential 
Organ Failure Assessment score) and APACHE 
II scores (Acute Physiology and Chronic Health 
Evaluation). Serial measurements of serum 
procalcitonin can be of greater value in monitoring 
response to treatment in septic shock. Decreasing 
procalcitonin levels in patients with sepsis indicate 
effective treatment of the underlying infection. 
Persistently elevated procalcitonin levels indicate 
a possible treatment failure. When integrated into 
the management of septic patients, procalcitonin 
can help clinicians to manage septic patients more 
efficiently. 
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Figure 1. Algorithm for guidance of antibiotic initiation and modification proposed by Müller B et al. Int J Antimicrobial Agents. 
2007, 30S:S16-S23
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e
>1.0 
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ncouraged 
Strongly consider antibiotic initiation in all patients with suspicion of infection
Utility in Paediatrics
Adding procalcitonin results to clinical assessment 
improves the accuracy of the early clinical diagnosis 
of sepsis in neonates. It can also be used in the 
early diagnosis of bacterial meningitis. It is a useful 
biomarker in differentiating bacterial from non-
bacterial meningitis.
Useful in Neutropenic Patients
Several published studies have shown that the 
procalcitonin levels accurately predicted blood 
culture positivity in patients with neutropenia. 
Procalcitonin measurement also demonstrated the 
potential to reduce the number of blood cultures 
drawn in the Emergency Department to better 
implement resources. Several studies have shown 
that the use of procalcitonin in targeting rational 
blood culture utilization allows for more directing 
allocation of limited health-care resources.
                                        
Prediction of Renal Involvement in Paediatric 
Urinary Tract Infection
Urinary tract infection (UTI) in young children 
carries the risk of parenchymal damage and sequelae. 
The location of the infection within the urinary tract 
influences decisions regarding both therapeutics and 
follow-up. Because clinical features and laboratory 
markers of infection at an early age are not specific, 
it is difficult to make a distinction between lower 
UTI and acute pyelonephritis. Procalcitonin values 
have been proved to be more specific for identifying 
patients who might develop renal damage.
Utility in Organ Transplants Rejection
Procalcitonin possesses both sensitivity and 
specificity in identifying infection complications 
among patients undergoing solid organ 
transplantation. It is useful in differentiating acute 
graft rejection after solid organ transplantation from 
bacterial infections.
Antibiotic Stewardship
Müller and colleagues have recommended a 
procalcitonin guided diagnostic algorithm for 
patients with suspected sepsis. This is based on 
data available to date that discourages use of 
antibiotics at 0.1 - 0.25 ng/mL of procalcitonin 
levels. Whereas at the levels of >0.5 ng/
mL use of antibiotics is encouraged. A rising 
procalcitonin after starting treatment should 
prompt a review of antibiotics or source control 
in patients with systemic infections. In four 
intervention trials enrolling more than 1200 
patients, the success of this algorithm was 
measured by clinical outcomes, assuming that, 
if the patient recovered without antibiotics, then 
there was no serious bacterial illness.  Literature 
shows reduction in the antibiotic prescription 
rate by 40-50 per cent in patients with lower 
respiratory tract infection by procalcitonin 
guided stewardship. Procalcitonin at low 
concentrations can help to differentiate patients 
with clinically relevant lower respiratory tract 
infection who require antibiotic therapy from 
those with viral infection or minor bacterial 
infection who do not require antibiotic treatment.
ti i ti
r com endati
7VOL. 42, ISSUE 3DECEMBER 2016
TRALI is a syndrome characterized by the 
development of new onset acute respiratory 
distress with hypoxemia (SpO2 <90%  on room 
air) during or up to six hours after completion 
of a blood transfusion.  The incidence of 
TRALI has been reported to be one in 2000 to 
one in 7500 transfusions. However, it is felt 
worldwide that TRALI is an under-recognized 
and under-reported entity because of lack of 
awareness.
Diagnosis of TRALI
 
TRALI is a clinical diagnosis. It should be 
considered whenever a patient develops hypoxemic 
respiratory insufficiency during or shortly after 
transfusion of any blood product. The clinical and 
radiologic findings in TRALI are as follows:
Clinical Findings
Dyspnea, hypoxemia and bilateral pulmonary 
edema. Other reported findings include hypotension, 
tachycardia and fever (1-2°C rise from baseline). 
Radiological Findings
  
Characteristic chest x-ray results show 
bilateral patchy infiltrates, with alveolar and/
or interstitial patterns. The chest x-ray may 
indicate non-cardiogenic pulmonary edema 
without cardiac enlargement or other evidence 
of fluid overload.
Blood Products Implicated in Causing TRALI
All blood products have been associated with 
TRALI. Products with high plasma content such as 
fresh frozen plasma, apheresis platelet concentrates 
and whole blood have been associated with the 
greatest risk.
Etiology
TRALI may be attributable to the presence of 
anti-HLA and/ or anti-granulocyte antibodies in the 
plasma of multiparous females or donors who have 
received previous transfusions.
Pathogenesis
A “Two-Hit theory” has been proposed in the 
pathogenesis of TRALI: 
1. Antibodies to white blood cell antigens (HLA,  
 granulocyte and monocyte) present in the  
 donor’s plasma bind to the white cells of the 
 recipient which results in activation of 
 complement and neutrophils. The aggregation of 
 white cells within the lungs, and subsequent 
 adhesion to the capillary endothelium produce 
 endothelial damage, capillary leakage and the 
 development of pulmonary edema.
2. The clinical condition of the patient (e.g. 
 sepsis, trauma, etc) causes sequestration of 
 primed neutrophils in the activated pulmonary 
 endothelium. This results in endothelial damage, 
 capillary leakage and the subsequent 
 development of pulmonary edema. The two-
 event theory may explain the development of  
 TRALI when there is no evidence of donor 
 HLA/HNA antibodies.
Treatment
Treatment of TRALI is supportive. Mild forms of 
TRALI usually respond to supplemental oxygen 
therapy. Severe forms require mechanical ventilation 
and ICU support.  There is no role for diuretics or 
corticosteroids. The majority of patients recover 
within 72 to 96 hours. However, some patients are 
slower to recover and may remain hypoxic with 
persistent pulmonary infiltrates up to seven days. 
Approximately five to ten per cent of cases are fatal 
in spite of aggressive supportive care.
Importance of Diagnosing and Reporting TRALI
Transfusion-related acute lung injury (TRALI) is 
a rare but potentially fatal complication of blood 
product transfusion. The diagnosis and reporting 
of TRALI will allow better understanding of the 
incidence, clinical course and associated mortality 
of this reaction. Furthermore, by identifying cases of 
TRALI, steps can be taken to prevent further cases 
of TRALI by investigating donors involved in these 
cases and deferring them from further donations if 
they are found to be implicated. 
TRALI
Dr Farheen Karim
Haematology
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Detection of Partial “D”Antigen or “D Variant”
Huma Warsi 
Haematology 
D antigen is a protein with many parts, found 
on the surface of red blood cells. The D antigen 
is also known as the “Rh factor” and it tells us 
blood type. People are either D (Rh) negative or 
D (Rh) positive. The D antigen may show up only 
weakly. Red blood cells from these people are 
also Du positive. 
Weak D (DU) red cells have historically been 
defined as having a reduced amount of D antigen, 
requiring an indirect Antiglobulin test (IAT) for 
detection. The number of samples classified as 
weak D however, depends on the characteristics 
of the typing reagents, which have changed over 
the years. Weak D expression results primarily 
from single nucleotide mutations in RHD that 
encode amino acid changes predicted to be 
located intracellularly, or in the trans membrane 
regions of red blood cell rather than on the outer 
surface of the red cell.The mutations affect 
insertion of the protein in the membrane,reflected 
in the reduced number of D antigen sites on the 
red cells. 
Parial D red cells have historically been classified 
as D positive. These red cells were predicted to 
be missing portions of D and indeed the majority 
of partial D phenotypes is due to hybrid genes 
in which portions of RHD are replaced by the 
corresponding portions of RHCE. The novel 
sequences of the hybrid Protein resulting from 
regions of red joined to RhCE not only can result 
in the loss of D epitopes but also can generate 
new antigens. 
Clinical Significance During Pregnancy
Mothers who are “partial D” should be considered 
D (Rh) negative. These mothers could build up 
antibodies to the part of the “D” antigen they lack. 
If their baby is D (Rh) positive, the antibodies 
could destroy the baby’s red blood cells. This leads 
to hemolytic disease of the fetus and newborn, or 
“HDFN.” These mothers will need treatment during 
pregnancy to prevent HDFN.         
 
Source: Bloodblood journal. hematology library Vol 89 no 51779-1786
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Monoclonal Gammopathy of Undetermined 
Significance (MGUS)
Dr Muhammad Shariq Shaikh
Haematology
Monoclonal gammopathy of undetermined 
significance (MGUS) is defined as the presence 
in the serum of an M-protein <30 g/L, bone 
marrow clonal plasma cells <10 per cent, no 
end organ damage (CRAB: hypercalcemia, renal 
insufficiency, anaemia, bone lesions) and no 
evidence of B-cell lymphoma or other disease 
known to produce an M-protein. Paraprotein or 
M-protein refers to existence in blood of a single 
homogeneous (monoclonal) immunoglobulin 
typically secreted by expanded clone of terminally 
differentiated B cells. 
MGUS is an asymptomatic condition and 
is usually discovered unexpectedly. Typical 
laboratory and radiographic abnormalities are 
absent. Its prevalence is approximately three per 
cent in persons over age 50 which increases to 
more than five per cent beyond 70 years of age. 
It is more common in man (M:F 1.5:1) and more 
than twice as frequent in African Americans 
as in Caucasians. Common associations 
include connective tissue disorders, peripheral 
neuropathies, dermatological, endocrine and liver 
diseases. It may often be seen as a transient event 
following solid organ and bone marrow stem cell 
transplantation.
Approximately 70 per cent are IgG, 15 per 
cent IgM., 12 per cent IgA and three per 
cent are biclonal1. MGUS may consist of 
immunoglobulin light chain only in up to 20 
per cent and is only detected by serum free 
light chain assay. Bone marrow aspirate and 
trephine does not contribute to the diagnosis 
as plasma cells are not markedly increased. 
Immunophenotyping by flow cytometry however, 
frequently shows two populations of plasma 
cells, one with a normal immunophenotype 
(CD38 bright+, CD19+ CD56-) that is polyclonal 
and a monoclonal population with an aberrant 
phenotype, most often either CD19-/CD56+ or 
CD19-/CD56-. 
Although the prevalence may differ, abnormal 
karyotypes when present in MGUS are the 
same as those found in myeloma. Translocation 
involving immunoglobulin heavy chain (14q32) 
gene are detected in nearly 50 per cent of 
the cases with t( 11;14) (q23:q32) being the 
commonest translocation (15-25 per cent). 
Deletions of 13q are detected in 40-50 per cent 
cases however, its relation to progression of 
MGUS are not clear. Activating K- and NRAS 
mutations are much less frequent in MGUS (-5 
per cent) compared to myeloma (30-40 per cent). 
Although genetic alterations and gene expression 
patterns probably can distinguish advanced 
myeloma from MGUS there are no unequivocal 
intrinsic differences that distinguish MGUS from 
myeloma. 
M-protein levels remain stable with no other 
evidence of progression in most individuals. 
However, evolution to an overt plasma 
cell myeloma, amyloidosis, Waldenstrom’s 
macroglobulinemia and other lymphoproliferative 
disorder may occur at a risk of one per cent per 
year. Factors associated with increased likelihood 
of progression include higher M-protein level 
(>4 times with level of 25g/L to that of <5g/L), 
IgM or IgA MGUS, fraction of plasma cells in 
bone marrow with abnormal phenotype, DNA 
aneuploidy and subnormal levels of polyclonal 
immunoglobulins.
Thus, MGUS should be considered a pre-
neoplastic condition and patients should be 
appropriately counseled and followed by 
monitoring M-protein levels.
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Six Sigma is a statistical measure of quality for 
process improvement originally developed by 
Motorola in 1985. It is a metric that quantifies the 
performance of processes as a rate of Defects Per 
Million Opportunities (DPM, or DPMO). A Six 
Sigma-capable process has so little random variation 
that the standard deviation, when multiplied by six, 
gives a quantity that meets the customer requirement 
for that process. It sets a quantitative goal for process 
performance and in turn quality improvement. It was 
in March 1998 that Six Sigma was applied to the 
healthcare industry for the first time. The delivery of 
healthcare demands the highest level of quality and 
the most advanced quality management system. 
A Six Sigma process is one in which 99.9997 per 
cent of the products manufactured are statistically 
expected to be free of defects or errors (3.4 defects 
per million). (Table 1) Higher sigma values indicate 
Lena Jafri and Saba Azeem
Chemical Pathology
Understanding Six Sigma Methodology 
better performance and vice versa. Quality is 
assessed on the sigma scale with a criterion of three 
sigma as the minimum allowable sigma for routine 
performance and a sigma of 6 being the goal for 
world-class quality. 
Six Sigma projects follow two project methodologies 
with acronyms DMAIC and DMADV. Each 
methodology is composed of five phases. (Table 
2) To improve an existing process the DMAIC 
methodology is used and to implement a new process 
or product DMADV is used.
There are several key players involved in launching 
a Six Sigma project. Prior to starting a project, 
a multidisciplinary team is formed. Similar to 
martial arts system formal Six Sigma programs 
adopt a ranking terminology. For example ‘Black 
Belts’ and ‘Green Belts’, which denote people with 
different levels of expertise (and certification). Six 
Sigma ‘Black Belts’ use a vast array of tools at 
each stage of Six Sigma implementation to control 
variation in process quality, and to manage teams 
and communication. This helps in creating an 
infrastructure within the organization.
A major difference between Six Sigma and other 
quality programs is that Six Sigma incorporates a 
control phase with ongoing checks. This ensured 
that once improvement is achieved it is not 
temporary but is maintained over time. Six Sigma 
methodologies are well suited for application 
Table 1. Sigma Levels and Defects Per Million of Opportunities
Table 2. Tools to Dry Sig Sigma Projects
Sigma Level
Six Sigma
Five Sigma
Four Sigma
Three Sigma
Two Sigma
One Sigma
DPMO
3.4
233
6210
66810
308500
691500
Error Free Rate
99.9997%
99.977%
99.4%
93%
69%
31%
DMAIC
Define: process of interest that needs to be improved 
Measure: relevant data, measure performance
Analyze: what is affecting our processes
Improve/Innovate: redefine the process, remove cause, brain 
storming needed
Control: documentation of new process and training, monitor the 
process
DMADV
Define: goals as per customer demands and satisfaction
Measure: production capabilities and risks
Analyze: to develop alternatives
Design: an improved alternative
Verify: run pilot run to verify design
11
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to laboratory settings because of the inherent 
need for statistical precision and quality control in 
laboratory testing, as well as the highly repetitive 
nature of laboratory work. It can serve as a quality 
indicator for pre-analytical, analytical and post 
analytical processes. Six Sigma values can be 
calculated for quantitative assays (total allowable 
error – bias / CV), for internal quality control 
data and also in proficiency testing. The Clinical 
Laboratory Improvement Amendments of 1988 
and the Joint Commission on Accreditation of 
Healthcare Organizations requires laboratories to 
perform external comparison of their performance 
with others in a process commonly known as 
benchmarking. The data of Six Sigma studies and 
projects is evolving and it can become the tool for 
benchmarking and to compare laboratory error 
rates with peers.
Example
To better understand the calculations involved in 
sigma metrics  here is an example from laboratory 
practice.  A process improvement initiative using 
Six Sigma strategies between May to October 2013 
was taken at the Section of Chemical Pathology, 
Department of Pathology and Microbiology, Aga 
Khan University Hospital (AKUH) to reduce the 
STAT tests turnaround time in emergency department 
(ED) laboratory. A team led by pathologist and 
comprising of two senior technologists conducted 
the project using ‘Define Measure Analyze Improve 
Control’ (DMAIC) methodology. Review of total 
STAT data showed that 0.25 per cent STAT tests 
were not reported in one hour, which is the cutoff 
reporting time of Clinical Laboratory of AKUH. 
In the commencement of the project the problem 
was defined as average STAT delay of 14 out of six 
thousand samples per month (DMAIC). 
The approach adopted was direct observation and 
process analysis. Tests that exceeded one hour goal 
required for completion was considered a delay. 
The base line delay using Six Sigma calculator 
was 4.33 on sigma scale (DMAIC).  A group 
member was assigned to daily monitor and records 
the process flow of STAT delays along with the 
reason for the delay. Group met fortnightly and 
brain storming was done, corrective and preventive 
actions for each delay were taken (DMAIC). Root 
cause analysis identified delay in processing of 
specimens, instrument malfunctioning and their late 
rectification and interruption in data transmission 
through instrument to central information system. 
Frequency of delays was more in night shifts. 
Significant time was taken in sample processing 
because of inadequate staffing. and in answering 
phone calls by technologists during busy periods. 
On spot feedback mechanism after the delays did 
not exist (DMAIC). On the basis of root cause 
analysis technologists were educated about the 
importance of STAT test in patient care. Proper 
maintenance of instrument by evening staff was 
ensured to give support to night shift.  A new 
backup instrument with short throughput was 
arranged. Brief ED laboratory visit by senior 
technologist was arranged on daily basis to deal 
with staffing challenges, equipment problems, 
quality issues, and staff acknowledgments and 
feedbacks (DMAIC). Process of sample analysis 
from the time of sample receiving till sign out was 
revisited and a detailed workflow diagram was 
created and made available on the soft board for the 
technologists (DMAIC).To improve informing the 
results  of STAT tests with panic value a voice pager 
system was also introduced in the ED (DMAIC). 
On reanalysis of the number of STAT delays it was 
noted that it reduced from 4.33 to 5.01 on sigma 
scale. Impact of project was that STAT tests entries 
are now done on fast track. 
Applying Six Sigma methodologies in healthcare 
helps in improving issues of non-compliance 
and enhancing effectiveness in laboratory staff. 
Importance of Six Sigma in laboratory is gradually 
increasing and is a tool by which clinical laboratories 
can improve their processes and achieve their quality 
goals.
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Figure 2. Clean the sking over the venipuncture
Figure 1. Culture Bottle
Blood Collection for Culture
Dr Naima Fasih
Microbiology 
Purpose(s)
To ensure provision of safe, timely and convenient 
process for the patients undergoing of blood 
specimen collection.
Responsibility
All assigned consultants, registered nurses, assigned 
nursing staff, laboratory personnel and unit 
receptionist.
Equipment
Culture bottles (Two for adults and one for peads)
Skin disinfectant 
Option 1: Sterile alcohol swab and two per cent 
chlorhexidine glauconate in 70 per cent isopropyl 
alcohol impregnated swab
Option 2: Sterile alcohol swab and 10 per cent 
povidine iodine
Option 3: Sterile alcohol swab (only for <2 months 
children of age)
Clean Gloves
Syringe 10 ml (02)
Patient Identification sticker
Alcohol wipes to disinfect bottle septum
Tourniquet 
Procedure
Preparatory Phase
Explain procedure to patient/family. 
Verify the patient’s identification by checking the 
patient name and identification number. 
Wash or sanitize hands and wear latex gloves. 
Follow Standard Precautions for all patients.
Assemble necessary equipment before preparation of 
the patient’s skin. 
Check the expiry of the culture bottle.
Adult: Two bottles (One aerobic + One anaerobic)
Children: One bottle (paediatric)
Remove the cap from culture bottles. Clean septum 
with (sterile) alcohol wipe (do not use iodine as it 
damages the septum). Allow it to dry. 
(see Figure 1)
Procedure
Apply tourniquet to the extremity and identify the 
puncture/ phlebotomy site.
Preparation of the phlebotomy site.
Step 1: Vigorously cleanse the skin over the 
venipuncture site with 70 per cent isopropyl or ethyl 
alcohol to remove surface dirt and oils. Allow to dry. 
(see Figure 2)
Step 2: Disinfect a five centimeter area in concentric 
circles (see Figure 3), moving outward from 
center of the site using two per cent chlorhexidine 
glauconate in 70 per cent isopropyl alcohol 
(impregnated swab) or 10 per cent povidine iodine. 
Step 3: Leave the disinfectant to act for 60 seconds 
before venipuncture. 
Step 4: Clean patient’s skin again with alcohol swab.
13
VOL. 42, ISSUE 3DECEMBER 2016
Figure 3. Disinfect Area 
DO NOT touch the venipuncture site after 
preparation and prior to phlebotomy. 
Appropriate amount of Blood for Culture Draw 
Adult: 10 ml blood per culture bottle is 
recommended.
Children: 1ml/year of age
Order of Inoculating Blood Culture Bottles
Inoculate the aerobic bottle first followed by the 
anaerobic bottle.
Do not change needle during transferring of blood 
from one bottle to other.
If an inadequate amount of blood was obtained 
(less than 5 cc), and repeat phlebotomy cannot 
be performed; all blood should be preferentially 
inoculated in the aerobic culture bottle.
Transport to Laboratory
As soon as possible.
In case of delay bottle should be kept at room 
temperature for 4hours.
Inoculated blood culture bottle will never freeze or 
refrigerate.
Enteric fever is a systemic infection with 
typhoidalSalmonella species, including Salmonella 
Typhi, S. Paratyphi A, B and C, which are 
transmitted through feco-oral route. The burden of 
typhoid and paratyphoid fever is highest in South 
Asia compared to the rest of the world especially 
in adolescents and children. Annual incidence of 
typhoid fever is around 250 to 500 per 100,000 
child-years in low socioeconomic communities 
of Karachi. The diagnosis is suspected on fever 
of more than three days duration, sore throat and 
abdominal pain. These are all nonspecific symptoms 
and could occur in other endemic infections, like 
malaria and dengue.
Traditionally the definitive diagnosis of enteric fever 
is by isolation of Salmonella Typhi or S. Paratyphi A, 
B or Cfrom blood, stool and bone marrow cultures. 
The sensitivity of blood culture ranges from 50 
per cent to 80 per cent with a specificity of 100 per 
cent. Sensitivity of blood cultures in diagnosing 
typhoid fever in many parts of the developing 
world is further limited because of prior antibiotics. 
Inadequacies of Salmonella Serology for 
Diagnosing Enteric Fever
Dr Joveria Farooqi
Microbiology
Although bone marrow cultures may increase the 
likelihood of bacteriologic confirmation of typhoid, 
these are difficult to obtain and relatively invasive. 
The greatest advantage of culture-based diagnosis 
is availability of susceptibility profile of the isolate. 
This can direct physician to prescribe appropriate 
antibiotic therapy ensuring cure and eradication, thus 
reducing transmission.
Detection of raised titers of agglutinating serum 
antibodies against the lipopolysaccharide (LPS) (O) 
or flagellum (H) antigens of serotype Typhi (the 
Widal test) has been in use for a long time.The Widal 
test is easy, inexpensive, and relatively noninvasive. 
It can be of diagnostic value when blood cultures 
are not available or practical. The results must be 
interpreted cautiously because of the low sensitivity 
of the test. The serologic diagnosis of typhoid is 
also fraught with problems because results of a 
single Widal test may be positive in only 50 per 
cent of cases in endemic areas, and serial tests may 
be required in cases presenting in the first week of 
illness.
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Detection of specific antibodies to typhoidal 
Salmonellae (Typhi dot) is also used as supportive 
tests for typhoid diagnosis. Rapid salmonella 
serological tests, which detect IgM and IgG 
antibodies to a Salmonella typhi-specific outer 
membrane protein, were considered sensitive and 
specific for the diagnosis of enteric fever when 
they were first introduced. Serological diagnosis 
has its own limitations. Initial studies showing high 
sensitivities were hopeful because of the chance of 
detecting typhoid earlier. It soon became evident 
that high sensitivity meant large number of false 
positive results; implying 10-15 days of unnecessary 
antibiotic therapy administered to patients without 
enteric fever. Antibodies against other gram-negative 
bacteria, like E. colifrom urinary infection and non-
typhoidal Salmonella species causing diarrhoea; 
viruses, e.g. dengue; and even malaria can cross-
react with the Salmonella-OMP in the kit, thus giving 
rise to false positive results. 
False negative results are also a problem when 
the test is performed in the first week of infection. 
Sensitivity (40-77 per cent) and specificity (80-95 
per cent) of serological tests for enteric fever is 
inadequate for clinical diagnosis considering its 
high prevalence in Pakistan. Therefore, experts 
recommend that these serological tests should not 
be used for diagnosis of enteric fever, except as 
evidence of past infection.
Detection of Salmonella DNA in blood and urine 
through nested or multiplex PCR have yielded 
hopeful results, but it is still not established as a 
diagnostic method for enteric fever. There is a need 
for more efficient rapid diagnostic test for typhoid 
especially during the acute stage of the 
disease. Until then, culture remains the 
method of choice and it becomes even 
more important to curtail the use of 
antibiotics before blood cultures are sent.
In view of this evidence recent 
recommendations based on high quality 
data from studies conducted in endemic 
areas strongly discourage the use of 
such tests for enteric fever.Thus, in 
keeping with international evidence-
based recommendations, the Aga 
Khan University Clinical Laboratories 
will shortly discontinue rapid typhoid 
serological test.
For diagnosis of typhoid fever, blood, 
stool and bone marrow cultures are gold 
standard, and are advised in suspected 
cases. 
CURRENT DIAGNOSIS
l     In the absence of localizing signs, the early stage of the   
 disease may be difficult to differentiate from other endemic  
 diseases such as malaria or dengue fever.
l     The presentation and diagnosis of typhoid fever may be 
 tempered by coexisting morbidities and early administration 
 of antibiotics.
l     The presentation of typhoid may be more dramatic in children 
 younger than 5 years of age, with comparatively higher rates 
 of complications and hospitalization.
l    The sensitivity of blood cultures in diagnosing typhoid fever 
 may be limited in many developing countries because of 
 antibiotic prescribing.
l     Multidrug-resistant (MDR) typhoid is a more severe clinical 
 illness with higher rates of toxicity and complications. In 
 particular, recent cases of quinolone-resistant typhoid may be 
 more severe.
Routine Screening for Macroprolactin in 
Hyperprolactemic Sera 
Dr Noreen Sherazi
Chemical Pathology 
prolactin” with a molecular weight over 100 kDa 
which is also called macroprolactin (MaPRL). In the 
majority of cases, MaPRL consists of monomeric 
prolactin connected with immunoglobulin; most 
It is well established that prolactin occurs mainly 
in three molecular forms: a monomeric prolactin 
with molecular weight ~ 23 kDa; a larger form 
named “big prolactin” (~50 kDa) and a “big, big 
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Introduction
The Alpha thalassaemia is an inherited disorder of α 
globin gene, which encompasses all those conditions 
in which deficit production of α globin chain of 
hemoglobin (Hb) occurs. Due to underproduction 
of α globin chain, γ and β globin chain synthesis is 
excessively increased to compensate during fetal and 
adult life.
Individuals having mutation in one allele of α globin 
gene on chromosome 16 are said to have 
α thalassaemia trait, they may be associated 
with mild anemia or with normal hemoglobin. 
Compound heterozygotes and some homozygotes 
for α-thalassaemia have moderately severe anemia 
characterized by presence of HbH disease. In 
neonatal period some individual who make very little 
or no alpha globin chains have a very severe form of 
anemia which, if untreated, causes death called the 
Hb Bart’s hydrops foetalis syndrome.
Genetics of Alpha Globin
Alpha globin gene is located on chromosome 16 
(16p 13.3) whereas beta globin gene resides on 
chromosome 11 (11p 15.4). There are two functional 
α genes present on each chromosome 16.The size 
of the cluster gene is 70 kb which consist of three 
pseudo gene ψ, έ, ά2, and ά1 and four functional 
genes, έ, ά2, ά1 and φ. α gene carry three exon and 
two introns. While, 10 variable number of tandem 
frequently type G. The predominant isoform 
of prolactin in healthy people, and also in most 
individuals with hyperprolactinemia, is a monomeric 
molecule which amounts to more than 85 per cent of 
circulating hormone. However, in some patients with 
hyperprolactinemia, the dominant form becomes 
MaPRL, which in normal conditions does not exceed 
two per cent of total serum prolactin. 
MaPRL is biologically inactive because the large 
molecular size of this complex prevents its crossing 
through the capillary blood barrier and reaching 
target cells. The percentage of hyperprolactinaemic 
patients with macroprolactinaemia have been 
studied several times, and ranges from 10 per cent 
to 45 per cent in literature. Among methods used 
to detect MaPRL, gel filtration chromatography is 
acknowledged to be the gold standard, but it is highly 
complex, time-consuming, and expensive procedure 
prohibits its use in routine screening for MaPRL. 
The polyethylene glycol precipitation test is widely 
used to detect pseudohyperprolactinemia caused by 
MaPRL. Current best practice recommends that all 
sera with increased total prolactin concentrations be 
sub fractionated by PEG precipitation to measure 
the bioactive monomeric prolactin concentration, 
a more clinically meaningful variable. Sub 
fractionation with PEG allows laboratories to 
distinguish patients with true hyperprolactinemia, in 
which there are supraphysiological concentrations 
of bioactive monomeric prolactin, from those 
with macroprolactinemia, which is characterized 
by increased concentrations of MaPRL together 
with normal concentrations of bioactive 
monomeric prolactin. In the absence of PEG 
screening, misdiagnosis and consequent clinical 
mismanagement along with financial burden on 
patients with hyperprolactinemia can occur.
We at  the Section of Chemical Pathology, 
Department of Pathology and Microbiology, 
Aga Khan University Hospital in the interests of 
clarity and good laboratory practice, have recently 
started routine screening of MaPRL in specimens 
having high total prolactin levels (i.e. above the 
reference interval till 200 ng/ml). Gel tube with 
5-7 cc of clotted blood or serum is required. We 
will report results as absolute monomeric prolactin 
concentration, together with an appropriate reference 
interval i.e. males 3.6 – 12.4 ng/ml and females 4 
– 18.5 ng/ml. This will have overall clinical impact 
on diagnosis, management and cost effectiveness 
proving to be a beneficial quality improvement 
initiative.
Molecular Analysis of Alpha Thalassaemia by 
Multiple Ligation Probe Assay
Azra Samreen and Dr Zeeshan Ansar Ahmed
Molecular Pathology
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repeats are located around α globin gene locus. Two 
α genes lie adjacent to each other. As each diploid 
cell contains two sets of each chromosome, hence 
there are four alpha globin alleles are present in a 
normal individual Figure 1.
Epidemiology
The prevalence of α thalassaemia is also like others 
common globin gene disorder 
(β thalassaemia and sickle cell trait). It demonstrates 
high frequency throughout all the tropical and 
subtropical region of the world. In some areas, 
the carrier frequency of α- thalassaemia may be 
as high as 80-90 per cent of the population. Of all 
globin disorders, α- thalassaemia is the most widely 
distributed and therefore many individuals in these 
areas have interacting combinations of these variants 
(e.g. both α and β thalassaemia). Due to differences 
in the interactions between various molecular 
defects underlying α- thalassaemia, HbH disease is 
predominantly seen in South East Asia, the Middle 
East and the Mediterranean. Similarly the Hb Bart’s 
Hydrops foetalis syndrome is predominantly seen in 
South East Asia.
Molecular Analysis
Due to advent of latest molecular tools, it has 
becomes possible to accurately and rapidly diagnose 
Alpha Globin Gene Cluster
Chromosome 16
Zeta 2  Zeta 1  Alpha 2  Alpha 1
5’  -  3’
HbA1
Figure 1. Diagramatic representation of α globin gene on chromosome 16
α- thalassaemia, while identify the precise defects 
underlying these disorders. Ultimately, most α globin 
chain rearrangements have been characterized by 
MLPA and DNA sequence analysis. For suspected 
but currently unknown rearrangements, Southern 
blotting or MLPA analysis may be used. Southern 
blot was the classical method to detect deletions 
causing α-thalassaemia before new techniques 
were introduced. Currently, MLPA is the method of 
choice. It is based on ligation of multiple probe-pairs 
hybridized across a large region of interest, followed 
by semi-quantitative amplification using universal 
tag PCR primers and subsequently fragments 
analysis.
Method
MLPA is performed on DNA samples for analysis 
alpha thalassamia. It can detect both deletion and 
duplication of alpha globin gene. The protocol 
consists of five steps spread on two days. MLPA test 
for alpha thalassemia is offered by the Molecular 
Pathology Section.
The steps are follows:
1. Hybridization reaction overnight incubation -  
 Day one
2. Ligation of probes – Day two
3. PCR amplification Day – two
4. Capillary Electrophoresis
5. Interpretation of data
Table 1. Different Types of Alpha Thalassaemia Based on Deletion Type Mutation
Genotypes
αα/αα
-α/αα
-α/-α or --/αα
--/-α
--/--
Description 
Normal –All four α alleles are present
Only one α allele absent 
Genetically silent carrier
Two α alleles are absent
Heterozygous or Homozygous trait
Three α alleles are absent
HbH  disease 
Totally absent α chain
Hydrops fetalis 
Symptoms
Normal heamatological profile
Clinically asymptomatic usually, diagnosed during antenatal 
screening
Mild hypochromic, microcytic anemia
(iron deficiency) 
Moderate anemia, jaundice and 
Hepato- splenomegaly
(folate deficiency)
Intrauterine death, skeletal deformities, cardiovascular problems, 
growth retarded 
17
VOL. 42, ISSUE 3DECEMBER 2016
Table 2. Alpha-Thalassaemia Mutations in Different Ethnic Groups
Ethnic Group
India 
Middle East
South-East Asia
Type of Thalassaemia
α+
α+ - α0
α0
α+
α+ - α0
α0
α+
Mutation(s)
- α3.7
- α4.2
α Koya Dora α
α IVS I-117 α
α PA3(AATA- -) 
- - MED 1
- α3.7
α PA1(AATAAG) 
- - SEA
- - FIL 
- -THAI
 
- α3.7
- α4.2 
α Constant Spring  
α Suan Dok
α Quong Sze 
α Pakse
α init A-G
α init -TG 
Occurrence
Common 
Less common 
Relatively rare
 
Relatively rare
Also found in Hindustani from Surinam
Common in Iran, Palestinians, Arab population
Common in Iran, Palestinians, Arab population
Relatively common in Arab population
Most common deletion among Asians 
world wide
Mainly in Philippinians
Common among Thai
Relatively common
Relatively rare
One of the most common non-deletion
 
variants in Chinese
Highly unstable α-chain
Highly unstable α-chain
Highly unstable α-chain, found in Thai,
Laotian
Common in Vietnam
Common in South-East Asia
Source: Adapted from Barbara J. Bain, Haemoglobinopathy Diagnosis 2nd edition 2006 {Bain, 2006126/id}
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Figure 1. A model explaining the loss of some FLT3/ITD mutations at relapse
Prognostification of Acute Myeloid Leukemia 
with FLT 3 Mutation
Madiha Salahuddin & Dr Zeeshan Ansar Ahmed 
Molecular Pathology 
Introduction
Acute myeloid leukemia (AML) is a severe 
progressive malignancy that generally has short 
survival because of heterogenetic origin, less 
responsive to treatment and tendency to early 
relapse. Abnormal activity of receptor tyrosine 
kinase has long been the main pathogenic finding 
in leukomogenesis, such as mutant forms of KIT, 
ABL, and platelet-derived growth factor receptor 
(PDGF-R) are among the constitutively activated 
tyrosine kinases that have been identified. 
FMS-like tyrosine kinase-3 (FLT3) is a member of 
the PDGF-R subfamily of receptor tyrosine kinases, 
which was originally identified by its expression 
in hematopoietic stem/progenitor cells, and its 
importance in normal lymphohematopoietic stem 
cell function is now well established.
Structure and physiological role in haemopoiesis  
FLT3 gene located on chromosome 13 (13q12); 
it is comprised of 24 exons extending over 
more than 100 kilobases. FLT3 shares the 
structural features of the other members of 
its subfamily, namely five immunoglobulin-
like domains in extracellular region, a single 
transmembrane sequence, and, intracellularly, 
a short juxtamembrane portion followed by the 
interrupted kinase domain. FLT3 is expressed 
in virtually expressed in every tissue thus far 
examined. In human hematopoietic cells, FLT3 
expression is restricted to the CD34-positive 
fraction of bone marrow and a smaller fraction 
of CD34-negative cells destined to become 
dendritic cells. Its activation send message 
to biochemical pathways that promote cell 
growth and inhibit apoptosis during normal 
haemopoiesis. 
Pattern seen on agarose gel
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ITD/WtITD/Wt
ITD/Wt
LOH
“early”
ITD mutation
“late”
ITD mutation
Wt/Wt
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Figure 2. (A) Showing PCR products of FLT3 ITD & D835 on ethidium bromide stained-agarose gel
 (B) Showing EcoRV digested products of FLT3 D835 on ethidium bromide-stained agarose gel
Source: M Levis1 and D Small, FLT3: IT Does matter in leukemia; Leukemia (2003) 17, 1738–1752.
Biological Consequences of Abnormal FLT3 
Activation
Molecularly, mutation-activated FLT3 induces 
transformation in immature clonal neoplastic (Blast) 
cells Figure 1. These cell completely blocks G-CSF-
induced differentiation and suppresses the expression 
of myeloid transcription factors the profound 
biochemical consequences of its constitutive 
activation. FLT3 mutations have also been seen in 
myelodysplastic syndrome (MDS) in about 3-5 per 
cent of newly diagnosed patients. In MDS patients 
without FLT3 mutations, they sometimes appear 
when these patients progress to AML.
Significance of FLT3 in Leukemia
Expression of FLT3 has been identified in 
several types of leukemia and lymphoma. In 
addition, FLT3 expression was demonstrated 
in most pre-B cell, myeloid, and monocytic 
leukemia. Recently, it was discovered that FLT3 
is universally expressed in primary AML blasts. 
Moreover, FLT3 mutations at diagnosis have been 
found to be occasionally acquired at the time of 
relapse. In other types, a lesser portion of chronic 
myelogenous leukemia (CML) blast crisis, as 
well as chronic lymphocytic leukemia (CLL) and 
even T-cell ALL cells have been shown to express 
FLT3. A number of FLT3 activating mutations 
have been found in leukemia patients; the first of 
these to be identified was the FLT3/ITD mutation. 
Subsequent to this an activating point mutations at 
aspartate 835 (or isoleucine 836) in the activation 
loop of the FLT3 kinase domain was discovered. 
Both types of mutations are primarily found in 
AML. Patients with this abnormality were found 
to have an increased incidence of leukocytosis 
and a decreased overall survival (OS) when 
compared with patients without FLT3/ITD 
mutations. Numerous groups around the world 
have now confirmed and extended these findings 
in both adult and pediatric AML.
Method for FLT3 Detection
DNA is extracted by Qiagen Blood DNA isolation 
kit, from fresh bone marrow or peripheral blood. 
Extracted DNA is then subjected to amplification 
using ITD primers and also with D835 primers 
in separate PCR reactions. Amplified products 
for D835 mutation are digested with restriction 
enzyme EcoRV.  Gel electrophoresis is performed 
to analyze amplification and EcoRV digested 
products Figure 2. This test is being offered by 
the Molecular Pathology section, Department 
of Pathology and Microbiology, Clinical 
laboratories, AKUH.
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Figure 1. Principle of Mtb Interferon gamma release assay
Interferon Gamma Release Assay (IGRA) 
for Detection of Mycobacterium tuberculosis 
Infection in the Host  
Maheen Hassan, Zahida Amin & Madiha Salahuddin
Molecular Pathology 
Background
Tuberculosis (TB) is the leading cause of death 
and a major cause of morbidity worldwide. 
Pakistan ranks sixth globally, among the 22 high 
TB burden countries, according to the World 
Health Organization (WHO). It is estimated that 
one third of the world’s population is latently 
infected with Mycobacterium tuberculosis 
(Mtb). However, only a small proportion of 
these progress to active disease. Traditionally, 
exposure to Mtb has been assessed with the 
use of a tuberculin skin test (TST) 
or Mantoux test. In a TST reaction, 
purified Mycobacterial peptide 
antigens are injected intra-dermally 
into the skin and a delayed type 
hypersensitivity response (DTH) to 
the antigens is measured after 48 h 
by measuring induration at the site 
of peptide injection. While this gives 
an indication of Mtb exposure in the 
host, it does not discriminate between 
Mtb and other mycobacteria of the 
Mtb complex such as M. bovis BCG. 
Therefore, the TST reaction is affected 
by BCG vaccination status of the host. 
Principle of the Assay
Test based on the principle that T-cells from a 
whole blood sample, when exposed and incubated 
with a specific Mtb antigen, will produce 
interferon-gamma (IFN-γ) in an individual who 
has been infected with Mtb (Figure 1). An IFN-γ 
release assay, commonly known as IGRA is one 
in which IFN-γ released by T cells in response 
to exposure to Mtb antigens is measured. The 
Quantiferon TB Gold In-Tube (QFT) is a whole 
blood based IGRA that measures the cell-
mediated immune response (IFN-γ) response 
to three specific proteins, ESAT-6, CFP-10 and 
TB7.7 which are found in Mtb but not in other 
species of the Mtb complex, such as M. bovis 
BCG. The QFT assay has two stages; firstly, it 
involves incubation of whole blood with TB-
specific antigen, control antigen (mitogen) and 
nil control. The TB antigen tube assesses the 
IFN-γ response to highly specific TB antigen, the 
negative control tube adjusts for background noise 
and the positive control tube (Mitogen) indicates 
the effectiveness of T-cell mediated responses in 
the patient. Secondly, plasma is harvested from 
tubes and IFN-γ level is determined by an enzyme 
linked immunoabsorbent assay (ELISA). 
Interpretation of the QFT Assay
The QFT is an indirect test for Mtb infection: 
T-cells reactive to Mtb specific antigens are only 
present in those infected with Mtb. Results are 
interpreted (as shown in Table 1). A test for Mtb 
is considered positive if the amount of IFN-γ in 
response to TB antigen (minus Nil) is >=0.35 
International Units (IU)/ml.
Utility of the Assay
The QFT - IGRA is intended for use as a 
diagnostic aid for Mtb infection, whether active 
tuberculosis disease or latent TB infection (LTBI), 
and is intended for use in conjunction with risk 
Antigen
Presenting
Cell (APC)
Antigen
Specific T 
Cell
Antigen
APC Processes
Antigen
APC Presents
Antigen to Antigen
specific T cell
APC specific T 
cell produces
IFN-γ
IFN-γ
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Table 1. Interpretation of IGRA – QFT Assay Results 
Interpretation Nil* TB Responset Mitogen Responset
assessment, radiography and other medical and 
diagnostic findings. It is useful for detection of 
Mtb in patients where differential diagnosis of 
this infection may lead to a change in treatment 
and management of the case. This is a qualitative 
test. The IFN-γ response to TB antigen should not 
be used to monitor disease progression. A QFT-G 
Positive result cannot distinguish between latent 
and active TB.
The advantage of this test is that specific antigens 
to Mtb are used and one patient visit is required. In 
contrast to TST, it is unaffected by BCG vaccine. 
Individuals who are on anti-inflammatory drug 
treatment such as tumor necrosis alpha (TNF-α) 
inhibitors for rheumatoid arthritis may be at risk 
of developing TB if they already have latent TB. 
In such cases, QFT may be useful assessing Mtb 
infection in rheumatic disease patients receiving 
immunosuppressive therapy. 
The disadvantage is that QFT is an expensive test 
and requires laboratory expertise. A factor which 
limits the efficacy of the QFT test is the cell 
mediated immune response in the host. Therefore, 
if immunity is compromised in the patient and T 
cell responses are diminished such as in patients 
with human immunodeficiency virus (HIV) 
infection, or those with oncological disorders, 
the QFT may give inaccurate results. However, 
QFT is more sensitive and specific then the TST 
for detecting tuberculosis infection in HIV +ve 
individuals. In children, the utility of QFT is 
still unclear as in young children cell mediated 
immune responses are not fully developed and 
this may result in false negative results. 
Positive
Negative**
Indeterminate++
* The interferon gamma (IFN-γ) concentration in plasma from blood incubated without antigen.
+ The IFN-γ concentration in plasma from blood stimulated with a single cocktail of peptides representing early
 secretory antigenic target-6 (EAST-6), culture filtrate protein-10 (CFP-10), and part of TB 7.7 minus Nil.
$  The IFN-γ concentration in plasma from blood stimulated with mitogen minus Nil.
 Interpretation indicating that Mycobacterium tuberculosis infection is likely.
** Interpretation indicating that M. tuberculosis infection is not likely.
++ Interpretation indicating an uncertain likelihood of M. tuberculosis infection.
Any
>0.5
<0.5
Any
>0.35 IU/ml and >25% of Nil
<0.35 IU/ml or <25% of Nil
<0.35 IU/ml or <25% of Nil
Any
<8.0
<8.0
<8.0
>8.0
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main cause identified was cannulation Figure 2. 
However, many injuries occurred during disposing 
of the used needles. In majority of cases the patients 
were not infected with any known blood borne 
infection. 
Over the years at institutions level as well 
as departmental level, we have regularly 
emphasized the importance of infection control 
and NSI particularly. Additionally, faculty as 
well as residents who are inducted, go through 
sessions and training for intervention procedures 
where they are taught measures to be taken 
when such an event occurs. Similar sessions are 
conducted for Technologists and Nursing staff as 
well. 
Timely surveillance is performed if a needle 
stick injury does occur. However, the best 
measure is prevention which can only be done 
by repeated re-enforcements through various 
techniques e.g. flyers, videos and lectures.
An Analysis of Needle Stick Injury in the 
Department of Radiology
Amin Rajani and Raza Sayani
Department of Radiology
Figure 1: Percentage of house staff with needle stick injuries
Figure 2: causes of needle stick injuries
Needle stick injury is a global issue 
and a major threat to health care 
workers. Occupational exposures to 
percutaneous injuries are a substantial 
source of infections with blood borne 
pathogens such as hepatitis B virus, 
(HBV), hepatitis C virus, (HCV) or 
Human immunodeficiency virus, 
(HIV) among health-care workers. 
NSI’s are generally under reported 
and data regarding them are usually 
sparse, especially in developing 
countries like Pakistan. Obtaining 
accurate figures for the incidence 
of needle stick injuries is very 
difficult. Its frequency in Radiology 
Department is generally considered 
low as compared to surgery; however 
the Radiology Department staff and doctors are no 
exemption. The frequency is increasing with the 
rise in interventional procedures in the department. 
We carried out a cross sectional survey in our 
department to identify the frequency by recording all 
self-reported needle stick injury data of health care 
workers of the department.
In the last decade (year 2000-2010), 55 health 
workers reported NSI. Radiographers and radiology 
residents received maximum injuries Figure 1. The
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